RecruitingNot ApplicableNCT05764551
The Application of Serum DNA Methylation for Patients With HCC
he Application of DNA Methylation for Patients Who Had Hepatocellular Carcinoma With Normal Serum Alpha-fetoprotein
Sponsor
Chiayi Christian Hospital
Enrollment
100 participants
Start Date
Mar 28, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this single-arm prospective study is to evaluate the application of serum DNA methylation for HCC patients with normal alpha-fetoprotein. The main question it aims to answer is . Is the dynamic change of serum DNA methylation correlated to recurrence or treatment response of HCC
Eligibility
Min Age: 20 Years
Inclusion Criteria4
- Age ≥ 20 years old
- The diagnosis of hepatocellular carcinoma (HCC) according to AASLD 2018 clinical guidelines or histology report
- Individuals with HCC and normal serum alpha-fetorpotein level (\<20 ng/ml)
- Individuals who could sign informed consent
Exclusion Criteria6
- The histology report revealed non-HCC, HCC mixed with cholangiocarcinoma or sarcomatoid HCC
- Individuals with HCC and other concurrent malignancies
- Individuals with chronic kidney disease who could not tolerate contrast-enhanced dynamic images
- Individuals ever receiving any organ transplantation
- Individuals with HIV infection
- Individuals who could not able to understand and sign informed consent
Interventions
DIAGNOSTIC_TESTSerum DNA methylation
Serum DNA methylation
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05764551
Related Trials
Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients
NCT056298451 location
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors
NCT060775911 location
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
NCT0552895214 locations
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
NCT054683592 locations
Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab
NCT0679611410 locations